We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 22% below its sector, cheaper than its peers on earnings.
InnoCare Pharma Limited, a biopharmaceutical enterprise, specializes in the discovery, development, and commercialization of therapeutic agents for oncological and autoimmune disorders. Its lead product, Orelabrutinib, a BTK inhibitor, addresses a wide range of conditions, including various forms of relapsed and/or refractory (r/r) lymphomas (such as chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, specific diffuse large B-cell lymphomas, and central nervous system lymphoma). It also targets systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder, sometimes utilized in combination therapies. The company's robust pipeline features several key candidates: ICP-192, a pan-FGFR inhibitor in Phase I/II clinical trials for solid tumors, notably cholangiocarcinoma and head and neck cancer; ICP-723, a pan-TRK inhibitor undergoing Phase I evaluation for cancers positive for neurotrophic tyrosine receptor kinase fusion; ICP-332, a novel tyrosine kinase 2 inhibitor in Phase I for autoimmune diseases; and ICP-B02, a bispecific antibody developed for lymphoma treatment. Furthermore, InnoCare is advancing ICP-189, ICP-915, and ICP-B03 for solid tumors; ICP-033 for liver cancer, renal cell carcinoma, colorectal cancer, and other solid malignancies; ICP-488 for autoimmune conditions; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody targeting various cancers; ICP-248 for hematological indications; and ICP-490 for both hematology and autoimmune disorders. In addition, the firm offers ICP-B04 (Tafasitamab) for the treatment of DLBCL and other hematological conditions. InnoCare Pharma Limited was established in 2015 and maintains its headquarters in Beijing, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 9969.HK and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
